NASDAQ:ALXN - Alexion Pharmaceuticals Stock Price, News, & Analysis

Sign in or create an account to add this stock to your watchlist.
$130.99 +0.78 (+0.60 %)
(As of 03/25/2019 02:06 PM ET)
Previous Close$130.21
Today's Range$128.30 - $131.65
52-Week Range$92.56 - $140.77
Volume975,871 shs
Average Volume1.44 million shs
Market Capitalization$29.27 billion
P/E Ratio18.48
Dividend YieldN/A
Beta1.55
Alexion Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes various therapeutic products. The company offers ULTOMIRIS (ALXN1210/ravulizumab-cwvz), a monoclonal antibody for the treatment of paroxysmal nocturnal hemoglobinuria (PNH), a genetic blood disorder; and Soliris (eculizumab), a monoclonal antibody for the treatment of PNH, atypical hemolytic uremic syndrome (aHUS), and generalized myasthenia gravis. It also provides Strensiq (asfotase alfa), a targeted enzyme replacement therapy for patients with hypophosphatasia; and Kanuma (sebelipase alfa) for the treatment of patients with lysosomal acid lipase deficiency. In addition, the company conducts Phase III clinical trials for ALXN 1210 (IV) that is in Phase III clinical trials for the treatment of PNH and aHUS; ALXN1210 (Subcutaneous), which is in Phase I for PNH and aHUS; and Soliris (eculizumab) for the treatment of myasthenia gravis and neuromyelitis optica spectrum disorder. Further, it develops ALXN1840 (WTX101) that is in Phase III clinical trials for the treatment of Wilson disease; and ALXN1830 (SYNT001), which is in Phase II clinical trials for the treatment of warm autoimmune hemolytic anemia. The company serves distributors, pharmacies, hospitals, hospital buying groups, and other healthcare providers in the United States, Europe, the Asia Pacific, and internationally. Alexion Pharmaceuticals, Inc. has collaboration and license agreement with Halozyme Therapeutics, Inc. to use drug-delivery technology in the development of subcutaneous formulations for its portfolio of products; collaboration with Dicerna Pharmaceuticals, Inc. to discover and develop RNAi therapies for complement-mediated diseases; and strategic agreement with Caelum Biosciences, Inc. to advance the development of CAEL-101 for light chain (AL) amyloidosis. The company was founded in 1992 and is headquartered in Boston, Massachusetts.

Receive ALXN News and Ratings via Email

Sign-up to receive the latest news and ratings for ALXN and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryBiotechnology
SectorMedical
Current SymbolNASDAQ:ALXN
CUSIP01535110
Phone475-230-2596

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$4.13 billion
Cash Flow$9.0965 per share
Book Value$41.08 per share

Profitability

Net Income$77.59 million

Miscellaneous

Employees2,656
Market Cap$29.27 billion
Next Earnings Date4/25/2019 (Estimated)
OptionableOptionable

Alexion Pharmaceuticals (NASDAQ:ALXN) Frequently Asked Questions

What is Alexion Pharmaceuticals' stock symbol?

Alexion Pharmaceuticals trades on the NASDAQ under the ticker symbol "ALXN."

How will Alexion Pharmaceuticals' stock buyback program work?

Alexion Pharmaceuticals declared that its Board of Directors has approved a share buyback plan on Sunday, April 9th 2017, which authorizes the company to buyback $1,000,000,000.00 in outstanding shares, according to EventVestor. This buyback authorization authorizes the company to repurchase up to 3.4% of its shares through open market purchases. Shares buyback plans are typically a sign that the company's board believes its stock is undervalued.

How were Alexion Pharmaceuticals' earnings last quarter?

Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) issued its quarterly earnings data on Monday, February, 4th. The biopharmaceutical company reported $2.14 earnings per share for the quarter, topping analysts' consensus estimates of $1.60 by $0.54. The biopharmaceutical company had revenue of $1.13 billion for the quarter, compared to analyst estimates of $1.06 billion. Alexion Pharmaceuticals had a return on equity of 18.15% and a net margin of 1.88%. The firm's revenue was up 24.1% on a year-over-year basis. During the same period in the prior year, the business earned $1.48 earnings per share. View Alexion Pharmaceuticals' Earnings History.

When is Alexion Pharmaceuticals' next earnings date?

Alexion Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Thursday, April 25th 2019. View Earnings Estimates for Alexion Pharmaceuticals.

What guidance has Alexion Pharmaceuticals issued on next quarter's earnings?

Alexion Pharmaceuticals issued an update on its FY19 earnings guidance on Monday, February, 4th. The company provided EPS guidance of $9.10-9.30 for the period, compared to the Thomson Reuters consensus earnings per share estimate of $8.80. The company issued revenue guidance of $4.625-4.7 billion, compared to the consensus revenue estimate of $4.75 billion.Alexion Pharmaceuticals also updated its FY 2019 guidance to $9.10-9.30 EPS.

What price target have analysts set for ALXN?

15 Wall Street analysts have issued 1-year price targets for Alexion Pharmaceuticals' shares. Their predictions range from $123.00 to $190.00. On average, they anticipate Alexion Pharmaceuticals' stock price to reach $162.6429 in the next year. This suggests a possible upside of 23.9% from the stock's current price. View Analyst Price Targets for Alexion Pharmaceuticals.

What is the consensus analysts' recommendation for Alexion Pharmaceuticals?

15 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Alexion Pharmaceuticals in the last year. There are currently 3 hold ratings and 12 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Alexion Pharmaceuticals.

Has Alexion Pharmaceuticals been receiving favorable news coverage?

News headlines about ALXN stock have been trending positive this week, according to InfoTrie. The research group identifies negative and positive press coverage by monitoring more than six thousand blog and news sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Alexion Pharmaceuticals earned a coverage optimism score of 3.0 on InfoTrie's scale. They also gave media stories about the biopharmaceutical company a news buzz of 10.0 out of 10, indicating that recent press coverage is extremely likely to have an effect on the stock's share price in the immediate future.

Who are some of Alexion Pharmaceuticals' key competitors?

What other stocks do shareholders of Alexion Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Alexion Pharmaceuticals investors own include Celgene (CELG), Gilead Sciences (GILD), Alibaba Group (BABA), Micron Technology (MU), Netflix (NFLX), NVIDIA (NVDA), Allergan (AGN), Biogen (BIIB), Amgen (AMGN) and Visa (V).

Who are Alexion Pharmaceuticals' key executives?

Alexion Pharmaceuticals' management team includes the folowing people:
  • Dr. Ludwig N. Hantson, CEO & Director (Age 56)
  • Mr. Paul J. Clancy, Exec. VP & CFO (Age 57)
  • Mr. Brian Goff, Exec. VP & Chief Commercial Officer (Age 50)
  • Mr. Daniel A. Bazarko CPA, Chief Accounting Officer & Sr. VP
  • Ms. Susan Altschuller Ph.D., VP of Investor Relations

Who are Alexion Pharmaceuticals' major shareholders?

Alexion Pharmaceuticals' stock is owned by many different of retail and institutional investors. Top institutional investors include FMR LLC (11.81%), BlackRock Inc. (7.28%), Jennison Associates LLC (3.91%), Norges Bank (1.79%), Northern Trust Corp (1.30%) and Geode Capital Management LLC (1.20%). Company insiders that own Alexion Pharmaceuticals stock include Ann M Veneman, Bros Advisors Lp Baker, Christopher J Coughlin, Daniel Bazarko, Heidi L Wagner, Indrani Lall Franchini, John B Moriarty, John J Orloff, Julie O'neill, Ludwig Hantson and Paul J Clancy. View Institutional Ownership Trends for Alexion Pharmaceuticals.

Which major investors are selling Alexion Pharmaceuticals stock?

ALXN stock was sold by a variety of institutional investors in the last quarter, including Bessemer Group Inc., Orbimed Advisors LLC, Temasek Holdings Private Ltd, Bank of New York Mellon Corp, American Century Companies Inc., Eaton Vance Management, State of Tennessee Treasury Department and Sound Shore Management Inc. CT. Company insiders that have sold Alexion Pharmaceuticals company stock in the last year include Daniel Bazarko, Indrani Lall Franchini, John J Orloff, Ludwig Hantson and Paul J Clancy. View Insider Buying and Selling for Alexion Pharmaceuticals.

Which major investors are buying Alexion Pharmaceuticals stock?

ALXN stock was purchased by a variety of institutional investors in the last quarter, including FMR LLC, Norges Bank, Swedbank, Geode Capital Management LLC, Prudential PLC, Amundi Pioneer Asset Management Inc., Candriam Luxembourg S.C.A. and Iridian Asset Management LLC CT. Company insiders that have bought Alexion Pharmaceuticals stock in the last two years include Bros Advisors Lp Baker, Christopher J Coughlin and Ludwig Hantson. View Insider Buying and Selling for Alexion Pharmaceuticals.

How do I buy shares of Alexion Pharmaceuticals?

Shares of ALXN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Alexion Pharmaceuticals' stock price today?

One share of ALXN stock can currently be purchased for approximately $131.31.

How big of a company is Alexion Pharmaceuticals?

Alexion Pharmaceuticals has a market capitalization of $29.34 billion and generates $4.13 billion in revenue each year. The biopharmaceutical company earns $77.59 million in net income (profit) each year or $7.09 on an earnings per share basis. Alexion Pharmaceuticals employs 2,656 workers across the globe.

What is Alexion Pharmaceuticals' official website?

The official website for Alexion Pharmaceuticals is http://www.alexion.com.

How can I contact Alexion Pharmaceuticals?

Alexion Pharmaceuticals' mailing address is 121 SEAPORT BOULEVARD, BOSTON MA, 02210. The biopharmaceutical company can be reached via phone at 475-230-2596 or via email at [email protected]


MarketBeat Community Rating for Alexion Pharmaceuticals (NASDAQ ALXN)

Community Ranking:  3.2 out of 5 (star star star)
Outperform Votes:  1,096 (Vote Outperform)
Underperform Votes:  601 (Vote Underperform)
Total Votes:  1,697
MarketBeat's community ratings are surveys of what our community members think about Alexion Pharmaceuticals and other stocks. Vote "Outperform" if you believe ALXN will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ALXN will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 3/25/2019 by MarketBeat.com Staff

Featured Article: Straddles

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel